Jyotishri Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 8 Year, 23 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.34 M
as on 10-12-2024
- Revenue 42.89%
(FY 2021)
- Profit 39.49%
(FY 2021)
- Ebitda 1045.76%
(FY 2021)
- Net Worth 40.12%
(FY 2021)
- Total Assets -31.57%
(FY 2021)
About Jyotishri Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.34 M.
Anand Kumar and Ravi Gupta serve as directors at the Company.
- CIN/LLPIN
U36990UP2017PTC088884
- Company No.
088884
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Jyotishri Pharmaceuticals Private Limited offer?
Jyotishri Pharmaceuticals Private Limited offers a wide range of products and services, including Alcohol Solvents, Rectified Spirit.
Who are the key members and board of directors at Jyotishri Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Kumar  | Director | 03-Jan-2017 | Current |
| Ravi Gupta | Director | 03-Jan-2017 | Current |
Financial Performance of Jyotishri Pharmaceuticals.
Jyotishri Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 42.89% increase. The company also saw a substantial improvement in profitability, with a 39.49% increase in profit. The company's net worth Soared by an impressive increase of 40.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jyotishri Pharmaceuticals?
In 2018, Jyotishri Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.34 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
- Canara Bank : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Jun 2020 | Canara Bank | ₹0.34 M | Open |
| 13 Sep 2017 | Others | ₹2.00 M | Open |
How Many Employees Work at Jyotishri Pharmaceuticals?
Unlock and access historical data on people associated with Jyotishri Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jyotishri Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jyotishri Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.